The DOI matches its Crossref record; 244 of the 244 references it cites were found in a registry or an index.
Immune escape of tumors: apoptosis resistance and tumor counterattack
Abstract
Interactions between the immune system and malignant cells play an important role in tumorigenesis. Failure of the immune system to detect and reject transformed cells may lead to cancer development. Tumors use multiple mechanisms to escape from immune-mediated rejection. Many of these mechanisms are now known on a cellular and molecular level. Despite this knowledge, cancer immunotherapy is still not an established treatment in the clinic. This review discusses the immune escape mechanisms used by tumors with an emphasis on mechanisms related to apoptosis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Items 201–244 of 244
Kogan, S. C., Brown, D. E., Shultz, D. B., Truong, B.-T., Lallemand-Breitenbach, V., Guillemin, M.-C., Lagasse, E., Weissman, I. L., & Bishop, J. M. (2001) · The Journal of Experimental Medicine · doi:10.1084/jem.193.4.531 · Cited by 108
Rotem‐Yehudar, R., Groettrup, M., Soza, A., Kloetzel, P., & Ehrlich, R. L. (1996) · The Journal of Experimental Medicine · doi:10.1084/jem.183.2.499 · Cited by 106
Accelerated rejection of Fas ligand-expressing heart grafts.
Takeuchi, T., Ueki, T., Nishimatsu, H., Kajiwara, T., Ishida, T., Jishage, K., Ueda, O., Suzuki, H., Li, B.-X., Moriyama, N., et al. (1999) · Journal of Immunology · doi:10.4049/jimmunol.162.1.518 · Cited by 102
Onrust, S. V., Hartl, P. M., Rosen, S. D., & Hanahan, D. (1996) · Journal of Clinical Investigation · doi:10.1172/jci118406 · Cited by 99
Matsui, S., Ahlers, J. D., Vortmeyer, A. O., Terabe, M., Tsukui, T., Carbone, D. P., Liotta, L. A., & Berzofsky, J. A. (1999) · The Journal of Immunology · doi:10.4049/jimmunol.163.1.184 · Cited by 92
Immunological ignorance of silent antigens as an explanation of tumor evasion
Chen, L. (1998) · Immunology Today · doi:10.1016/s0167-5699(97)01180-8 · Cited by 90
Shudo, K., Ryu, I., & Shigekazu, N. (2003) · Kanazawa University Repository for Academic Resources (DSpace) (Kanazawa University) · Cited by 89
Becker, J. C., Brabletz, T., Czerny, C., Termeer, C., & Bröcker, E. ‐. (1993) · International Immunology · doi:10.1093/intimm/5.12.1501 · Cited by 89
Higaki, K., Yano, H., & Kojiro, M. (1996) · Europe PMC (PubMed Central) · Cited by 89
Shimizu, M., Fontana, A., Takeda, Y., Yagita, H., Yoshimoto, T., & Matsuzawa, A. (1999) · The Journal of Immunology · doi:10.4049/jimmunol.162.12.7350 · Cited by 86
Sotomayor, E. M., Fu, Y., Lopez-Cepero, M. M., Herbert, L. M., Jimenez, J. J., Albarracin, C. T., & Lopez, D. M. (1991) · The Journal of Immunology · doi:10.4049/jimmunol.147.8.2816 · Cited by 86
The role of the Fas lytic pathway in a perforin-less CTL hybridoma.
Walsh, C. M., Glass, A. A., Chiu, V. K., & Clark, W. R. (1994) · The Journal of Immunology · doi:10.4049/jimmunol.153.6.2506 · Cited by 84
Increased soluble CD95 (sFas/CD95) serum level correlates with poor prognosis in melanoma patients.
Ugurel, S., Rappl, G., Tilgen, W., & Reinhold, U. (2001) · PubMed · Cited by 83
Inhibition of the alloantibody response by CD95 ligand
Arai, H., Chanz, S. Y., Bishop, D. K., & Nabel, G. J. (1997) · Nature Medicine · doi:10.1038/nm0897-843 · Cited by 81
Bonnotte, B., Larmonier, N., Favre, N., Fromentin, A., Moutet, M., Martin, M. S., Gurbuxani, S. K., Solary, É., Chauffert, B., & Martin, F. (2001) · The Journal of Immunology · doi:10.4049/jimmunol.167.9.5077 · Cited by 80
Immune Response and Myoblasts That Express Fas Ligand
Kang, S., Hofmann, A., Le, D., Springer, M. L., Stock, P. G., & Blau, H. M. (1997) · Science · doi:10.1126/science.278.5341.1322 · Cited by 78
Immune evasion by tumours: involvement of the CD95 (APO-1/Fas) system and its clinical implications
Strand, S., & Galle, P. R. (1998) · Molecular Medicine Today · doi:10.1016/s1357-4310(97)01191-x · Cited by 77
Countering the 'counterattack' hypothesis
Restifo, N. P. (2001) · Nature Medicine · doi:10.1038/85357 · Cited by 74
The Regulation of CD95 Ligand Expression and Function in CTL
Li, J., Rosen, D., Ronen, D., Behrens, C. K., Krammer, P. H., Clark, W. R., & Berke, G. (1998) · The Journal of Immunology · doi:10.4049/jimmunol.161.8.3943 · Cited by 74
Self-citationMellado, M., de Ana, A. M., Moreno, M. C., Martínez‐A, C., & Rodríguez-Frade, J. M. (2001) · Current Biology · doi:10.1016/s0960-9822(01)00199-3 · Cited by 72
CD95 ligand in graft rejection
Yagita∥, H., Seino, K., Kayagaki, N., & Okumura, K. (1996) · Nature · doi:10.1038/379682a0 · Cited by 69
Clonal deletion of thymocytes as a tumor escape mechanism
Lauritzsen, G. F., Hofgaard, P. O., Schenck, K., & Bogen, B. (1998) · International Journal of Cancer · doi:10.1002/(sici)1097-0215(19981005)78:2<216::aid-ijc16>3.0.co;2-8 · Cited by 67
Blanchet, O., Bourge, J. F., Zinszner, H., Israël, A., Kourilsky, P., Dausset, J. B., Degos, L., & Paul, P. (1992) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.89.8.3488 · Cited by 66
Ehl, S. R., Hoffmann‐Rohrer, U., Nagata, S., Hengartner, H., & Zinkernagel, R. M. (1996) · The Journal of Immunology · doi:10.4049/jimmunol.156.7.2357 · Cited by 64
Seung, S. K., Urban, J. L., & Schreiber, H. W. (1993) · The Journal of Experimental Medicine · doi:10.1084/jem.178.3.933 · Cited by 60
Stress, NK Receptors, and Immune Surveillance
Pardoll, D. M. (2001) · Science · doi:10.1126/science.1066284 · Cited by 58
Li‐Weber, M., Laur, O., Hekele, A., Coy, J., Walczak, H., & Krammer, P. H. (1998) · European Journal of Immunology · Cited by 58
Self-citationImmunologic Nonresponsiveness to Tumors
Extermann, M., Antonia, S. J., & Flavell, R. A. (1998) · Critical Reviews™ in Oncogenesis · doi:10.1615/critrevoncog.v9.i1.30 · Cited by 53
Giovarelli, M., Musiani, P., Garotta, G., Ebner, R., Carlo, E. D., Kim, Y., Cappello, P., Rigamonti, L. M., Bernabei, P., Novelli, F., et al. (1999) · The Journal of Immunology · doi:10.4049/jimmunol.163.9.4886 · Cited by 53
Molenaar, J. J., Gérard, B., Pautas, C., Cavé, H., Duval, M., VILMER, E., & Grandchamp, B. (1998) · Blood · doi:10.1182/blood.v92.1.230.413k17_230_233 · Cited by 52
Volkmann, M., Schiff, J.-H., Hajjar, Y., Otto, G., Stilgenbauer, F., Fiehn, W., Galle, P. R., & Hofmann, W. J. (2001) · Journal of Molecular Medicine · doi:10.1007/s001090100244 · Cited by 45
CD95 Ligand-Expressing Tumors Are Rejected in Anti-Tumor TCR Transgenic Perforin Knockout Mice
Behrens, C. K., Igney, F. H., Arnold, B., Mӧller, P., & Krammer, P. H. (2001) · The Journal of Immunology · doi:10.4049/jimmunol.166.5.3240 · Cited by 42
Self-citationUTILITY OF ADENOVIRAL-MEDIATED FAS LIGAND GENE TRANSFER TO MODULATE ISLET ALLOGRAFT SURVIVAL1
Judge, T. A., Desai, N. M., Yang, Z., Rostami, S. Y., Alonso, L. C., Zhang, H., Chen, Y., Markman, J. F., DeMateo, R. P., Barker, C. F., et al. (1998) · Transplantation · doi:10.1097/00007890-199808270-00003 · Cited by 40
A NON-CLEAVABLE MUTANT OF FAS LIGAND DOES NOT PREVENT NEUTROPHILIC DESTRUCTION OF ISLET TRANSPLANTS1
Kang, S., Braat, D., Schneider, D. B., O’Rourke, R. W., Lin, Z., Ascher, N. L., Dichek, D. A., Bækkeskov, S., & Stock, P. G. (2000) · Transplantation · doi:10.1097/00007890-200005150-00014 · Cited by 39
The great escape: Is immune evasion required for tumor progression?
Villunger, A., & Strasser, A. (1999) · Nature Medicine · doi:10.1038/11311 · Cited by 38
Gerharz, C. D., Ramp, U., Déjosez, M., Mahotka, C., Czarnotta, B., Bretschneider, U., Lorenz, I., Müller, M., Krammer, P. H., & Gabbert, H. E. (1999) · PubMed · Cited by 38
Self-citationKrammer, P. H. (1997) · Cell Death and Differentiation · doi:10.1038/sj.cdd.4400252 · Cited by 36
Self-citationSpecific and nonspecific immunity in the prevention of spontaneous tumours
Lollini, P., & Forni, G. (1999) · Immunology Today · doi:10.1016/s0167-5699(99)01450-4 · Cited by 21
Taylor, M. A., Chaudhary, P. M., Klem, J., Kumar, V., Schatzle, J. D., & Bennett, M. (2001) · The Journal of Immunology · doi:10.4049/jimmunol.167.8.4230 · Cited by 19
Exposing tumor cells to killer cell attack
Watzl, C., & Long, E. O. (2000) · Nature Medicine · doi:10.1038/78624 · Cited by 18
Okamoto, S., Takamizawa, S., Bishop, W. P., Wen, J., Kimura, K., & Sandler, A. D. (1999) · Journal of Surgical Research · doi:10.1006/jsre.1999.5613 · Cited by 14
CD95 Ligand expression enhances growth of murine renal cell carcinoma in vivo
Nishimatsu, H., Takeuchi, T., Ueki, T., Kajiwara, T., Moriyama, N., Ishida, T., Li, B., Kakizoe, T., & Kitamura, T. (1999) · Cancer Immunology Immunotherapy · doi:10.1007/s002620050548 · Cited by 13
Activation of the Ras-related GTPase Rap1 by thymocyte TCR engagement and during selection
(2000) · Pure Amsterdam UMC · doi:10.1002/1521-4141(200010)30:10 · Cited by 3
Bischof, A. (2000) · doi:10.1002/1521-4141(200003)30:3
Cited by
Immunosuppressive Strategies that are Mediated by Tumor Cells
Rabinovich, G. A., Gabrilovich, D., & Sotomayor, E. M. (2007) · Annual Review of Immunology · doi:10.1146/annurev.immunol.25.022106.141609 · Cited by 1,702
Angiogenic signaling pathways and anti-angiogenic therapy for cancer
Liu, Z.-L., Chen, H.-H., Zheng, L.-L., Sun, L.-P., & Shi, L. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01460-1 · Cited by 1,300
Translational biology of osteosarcoma
Kansara, M., Teng, M. W., Smyth, M. J., & Thomas, D. M. (2014) · Nature Reviews Cancer · doi:10.1038/nrc3838 · Cited by 1,294
Oncologic Photodynamic Therapy: Basic Principles, Current Clinical Status and Future Directions
Van Straten, D., Mashayekhi, V., De Bruijn, H., Oliveira, S., & Robinson, D. (2017) · Cancers · doi:10.3390/cancers9020019 · Cited by 1,012
Resistance to checkpoint blockade therapy through inactivation of antigen presentation
Sade-Feldman, M., Jiao, Y. J., Chen, J. H., Rooney, M. S., Barzily-Rokni, M., Eliane, J.-P., Bjorgaard, S. L., Hammond, M. R., Vitzthum, H., Blackmon, S. M., et al. (2017) · Nature Communications · doi:10.1038/s41467-017-01062-w · Cited by 1,005
Metadata
- Authors
- Igney, F. H., & Krammer, P. H.
- Venue
- Journal of Leukocyte Biology
- Publisher
- Oxford University Press (OUP)
- Published
- 2002-06-01
- Volume
- 71
- Issue
- 6
- Pages
- 907-920
- ISSN
- 0741-5400 (ISSN-L)
- 1938-3673
- OpenAlex
- W2281508338
- Cited by
- 468
- References
- 244
- FWCI
- 7.95
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.